摘要
目的探讨血清肿瘤异常蛋白(TAP)和糖类抗原125 (CA125)在乳腺癌患者新辅助化疗前后的水平变化及与疗效的关系。方法选取本院2017年1月至2019年1月收治的行新辅助化疗的乳腺癌患者80例为乳腺癌组,同期健康体检者40例为健康组,比较两组的血清TAP和CA125水平,分析乳腺癌患者的TAP和CA125水平与疗效的关系。结果乳腺癌组患者化疗前的血清TAP和CA125水平显著高于健康组(P<0.01)。乳腺癌患者的新辅助化疗有效率为47.50%;化疗有效组患者在化疗后的TAP和CA125水平显著低于化疗前(P<0.05),化疗无效组患者化疗后的TAP和CA125水平显著高于化疗前(P<0.05),化疗后有效组患者的TAP和CA125水平显著低于无效组(P<0.01)。ROC曲线分析显示,TAP联合CA125评估乳腺癌化疗有效性的敏感度、特异度、准确性和曲线下面积均显著高于二者单独评估(P<0.01)。结论乳腺癌患者在新辅助化疗后的血清TAP和CA125水平与化疗疗效密切相关,TAP和CA125可作为临床判定化疗疗效的可靠指标,二者联合使用具有更高的评估效能。
Objective To investigate the changes of serum tumor abnormality protein(TAP) and carbohydrate antigen 125(CA125)levels before and after neoadjuvant chemotherapy in patients with breast cancer and their relationship with efficacy. Methods 80 cases of breast cancer patients treated with neoadjuvant chemotherapy admitted to our hospital from January 2017 to January 2019 were selected as breast cancer group, and 40 cases of healthy examinees were selected as healthy group, to compare the levels of serum TAP and CA125 of two groups. The relationship of TAP and CA125 levels with efficacy of breast cancer patients was analyzed. Results Before chemotherapy,the levels of serum TAP and CA125 of breast cancer group were significantly higher than those of healthy group(P<0.01). The effective rate of neoadjuvant chemotherapy for breast cancer patients was 47.50%. The levels of TAP and CA125 in the effective group after chemotherapy were significantly lower than those before chemotherapy(P<0.05), while the levels of TAP and CA125 in the ineffective group after chemotherapy were significantly higher than those before chemotherapy(P<0.05);After chemotherapy, the levels of TAP and CA125 in the effective group were significantly lower than those in the ineffective group(P<0.01). ROC curve analysis showed that the sensitivity, specificity, accuracy and area under the curve of TAP combined with CA125 in the evaluation of chemotherapy effectiveness of breast cancer were significantly higher than those of TAP and CA125 alone(P<0.01). Conclusions The levels of serum TAP and CA125 in breast cancer patients after neoadjuvant chemotherapy are closely related to the efficacy of chemotherapy. TAP and CA125 can be used as reliable indicators to determine the efficacy of chemotherapy, and the combination has a higher evaluation efficiency.
作者
雷香菊
WEI Jinju(Department of Stomatology,Huizhou Hospital of Traditional Chinese Medicine,Huizhou 516001,China)
出处
《临床医学工程》
2019年第12期1656-1658,共3页
Clinical Medicine & Engineering
关键词
乳腺癌
新辅助化疗
肿瘤异常蛋白
糖类抗原125
疗效
Breast cancer
Neoadjuvant chemotherapy
Tumour abnormal protein
Carbohydrate antigen 125
Efficacy
